Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Safety and efficacy of linvoseltamab for patients with R/R multiple myeloma

Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses data from a Phase I/II trial (NCT03761108) investigating the BCMAxCD3 bispecific antibody, linvoseltamab, in patients with relapsed/refractory (R/R) multiple myeloma (MM). Dr Richter discusses the dose-response curve of this agent, and how further adjustment of dosage and treatment scheduling could improve efficacy and tolerability. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.